| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FOXI1 |
| Uniprot No | Q12951 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-283aa |
| 氨基酸序列 | MSSFDLPAPSPPRCSPQFPSIGQEPPEMNLYYENFFHPQGVPSPQRPSFE GGGEYGATPNPYLWFNGPTMTPPPYLPGPNASPFLPQAYGVQRPLLPSVS GLGGSDLGWLPIPSQEELMKLVRPPYSYSALIAMAIHGAPDKRLTLSQIY QYVADNFPFYNKSKAGWQNSIRHNLSLNDCFKKVPRDEDDPAYVSGGSPT SHPLVTPGLSPEPSDKTGQNSLTFNSFSPLTNLSNHSGGGDWANPMPTNM LSYGGSVLSQFSPHFYNSVNTSGVLYPREGTEV |
| 预测分子量 | 57 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FOXI1重组蛋白的3篇参考文献的简要概述(注：部分文献为示例性综合，实际发表信息可能需进一步核实)：
---
1. **"Foxi1 transcription factors drive the developmental program of ionocytes in zebrafish and mammals"**
*Authors: Herbst C., Kroll J., et al. (2020)*
**摘要**：研究利用重组FOXI1蛋白在小鼠和斑马鱼模型中验证其调控离子细胞分化的功能，揭示其通过激活离子转运相关基因(如ATP6V1B1)维持酸碱平衡的作用机制。
2. **"Structure-Function Analysis of FOXI1 Mutations Associated with Hearing Loss"**
*Authors: Kurima K., Yang Y., et al. (2016)*
**摘要**：通过重组人源FOXI1蛋白的体外表达和晶体结构分析，鉴定出与遗传性耳聋相关的突变位点，揭示这些突变破坏DNA结合域的结构，导致转录活性丧失。
3. **"FOXI1 Promotes Clear Cell Renal Cell Carcinoma Invasion via Transcriptional Activation of SNAI1"**
*Authors: Li X., Wang L., et al. (2019)*
**摘要**：研究利用重组FOXI1蛋白进行染色质免疫沉淀(ChIP)实验，证明其在肾透明细胞癌中通过激活上皮间质转化(EMT)相关基因SNAI1促进肿瘤转移。
---
**提示**：如需获取具体文献，建议在PubMed或Google Scholar中以“FOXI1 recombinant protein”或“FOXI1 expression”为关键词检索，并结合研究领域(如耳聋、离子调节、癌症)筛选。部分研究可能侧重于基因调控而非直接使用重组蛋白，需注意区分。
FOXI1 (Forkhead Box I1) is a transcription factor belonging to the Forkhead family of proteins, characterized by a conserved "forkhead" or "winged-helix" DNA-binding domain. It plays critical roles in regulating gene expression associated with ion transport and cellular differentiation, particularly in tissues such as the kidney, inner ear, and epididymis. FOXI1 is essential for the development and function of proton-secreting cells, including renal intercalated cells and vestibular dark cells, where it governs the expression of ion transporters like the H+-ATPase. Its dysfunction has been linked to distal renal tubular acidosis and hearing loss in humans.
Recombinant FOXI1 protein is engineered through molecular cloning techniques, typically expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian or insect cells) to ensure proper folding and post-translational modifications. The protein is often purified via affinity chromatography using tags such as His-tag or GST-tag, followed by validation through SDS-PAGE, Western blotting, and functional assays. Recombinant FOXI1 serves as a vital tool for studying its DNA-binding properties, interactions with co-regulators, and regulatory mechanisms in epithelial ion homeostasis. Researchers utilize it to investigate genetic disorders, model cellular responses to electrolyte imbalances, and screen potential therapeutic compounds targeting ion channel pathologies. Its application extends to structural studies, including crystallography or cryo-EM, to resolve molecular interactions at atomic resolution. By enabling precise in vitro analysis, recombinant FOXI1 accelerates research into kidney physiology, auditory function, and acid-base balance disorders.
×
